On the public citation graph
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer
0 signed · 916 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1016/s0140-6736(00)02034-1openalex-snapshot
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
inferredcites →https://doi.org/10.1016/s1470-2045(12)70477-1openalex-snapshot
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(14)70330-4openalex-snapshot
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
inferredcites →https://doi.org/10.1038/nm.3967openalex-snapshot
The consensus molecular subtypes of colorectal cancer
inferredcites →https://doi.org/10.1056/nejmoa032691openalex-snapshot
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.1056/nejmoa033025openalex-snapshot
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.1056/nejmoa0808268openalex-snapshot
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.1093/jnci/92.3.205openalex-snapshot
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
inferredcites →https://doi.org/10.1097/00000421-198212000-00014openalex-snapshot
Toxicity and response criteria of the Eastern Cooperative Oncology Group
inferredcites →https://doi.org/10.1200/jco.1990.8.9.1497openalex-snapshot
Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
inferredcites →https://doi.org/10.1200/jco.1992.10.6.896openalex-snapshot
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.
inferredcites →https://doi.org/10.1200/jco.2000.18.16.2938openalex-snapshot
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
inferredcites →https://doi.org/10.1200/jco.2004.05.113openalex-snapshot
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
inferredcites →https://doi.org/10.1200/jco.2004.11.037openalex-snapshot
Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment
inferredcites →https://doi.org/10.1200/jco.2005.08.037openalex-snapshot
Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry
inferredcites →https://doi.org/10.1200/jco.2007.12.5906openalex-snapshot
KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
inferredcites →https://doi.org/10.1200/jco.2007.14.9930openalex-snapshot
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
inferredcites →https://doi.org/10.1200/jco.2008.19.8135openalex-snapshot
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.1200/jco.2013.53.2473openalex-snapshot
PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.1200/jco.2014.56.5887openalex-snapshot
Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database
inferredcites →https://doi.org/10.1200/jco.2015.33.15_suppl.3585openalex-snapshot
Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405.
inferredcites →https://doi.org/10.1200/jco.2015.61.2887openalex-snapshot
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.1200/jco.2015.62.8495openalex-snapshot
Trying to Understand Differing Results of FIRE-3 and 80405: Does the First Treatment Matter More Than Others?
inferredcites →https://doi.org/10.1200/jco.22.02774openalex-snapshot
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4767642openalex-extracted
FUT2-Dependent Fucosylation of LAMP1 Promotes Apoptosis of Colorectal Cancer Cells by Regulating Autophagy-Lysosomal Pathway
inferred← citeshttps://doi.org/10.1001/jama.2017.6673openalex-snapshot
Cetuximab or Bevacizumab With First-Line Chemotherapy in Advanced KRAS Wild-Type Colorectal Cancer
inferred← citeshttps://doi.org/10.1001/jama.2021.0106openalex-snapshot
Diagnosis and Treatment of Metastatic Colorectal Cancer
inferred← citeshttps://doi.org/10.1001/jama.2023.4428openalex-snapshot
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer
inferred← citeshttps://doi.org/10.1001/jama.2026.1929openalex-snapshot
Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2019.3684openalex-snapshot
Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2020.23500openalex-snapshot
Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2023.46094openalex-snapshot
Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer
inferred← citeshttps://doi.org/10.1001/jamaoncol.2017.5314openalex-snapshot
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer
inferred← citeshttps://doi.org/10.1001/jamaoncol.2018.0518openalex-snapshot
Quantification of Long-term Survival Benefit in a Comparative Oncology Clinical Study
inferred← citeshttps://doi.org/10.1001/jamaoncol.2018.4465openalex-snapshot
Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer
inferred← citeshttps://doi.org/10.1001/jamaoncol.2019.1467openalex-snapshot
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer
inferred← citeshttps://doi.org/10.1001/jamaoncol.2020.0910openalex-snapshot
Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer
inferred← citeshttps://doi.org/10.1001/jamaoncol.2020.3938openalex-snapshot
Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer
inferred← citeshttps://doi.org/10.1001/jamaoncol.2021.5153openalex-snapshot
Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies
inferred← citeshttps://doi.org/10.1001/jamaoncol.2023.1088openalex-snapshot
Anti-EGFR Therapy for Left-Sided RAS Wild-type Colorectal Cancer—PARADIGM Shift
inferred← citeshttps://doi.org/10.1001/jamaoncol.2025.0604openalex-snapshot
Overall Survival in the CAIRO5 Clinical Trial
inferred← citeshttps://doi.org/10.1001/jamaoncol.2026.3634openalex-snapshot
Chemotherapy and Surgical Outcomes for Ovarian Metastases From Colorectal Cancer
inferred← citeshttps://doi.org/10.1002/14651858.cd015231openalex-snapshot
Neoadjuvant chemotherapy in locally advanced rectal cancer
inferred← citeshttps://doi.org/10.1002/1878-0261.13510openalex-snapshot
Lasting response by vertical inhibition with cetuximab and trametinib inKRAS‐mutated colorectal cancer patient‐derived xenografts
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm144openalex-snapshot
Carcinoma of the Colon and Rectum
inferred← citeshttps://doi.org/10.1002/9783527838561.ch14openalex-snapshot
Ovarian, Vaginal, and Vulvar Cancer
inferred← citeshttps://doi.org/10.1002/advs.202409147openalex-snapshot
Intratumoral Collagen Deposition Supports Angiogenesis Suggesting Anti‐angiogenic Therapy in Armored and Cold Tumors
inferred← citeshttps://doi.org/10.1002/ags3.12071openalex-snapshot
Recent advances in treatment for colorectal liver metastasis
inferred← citeshttps://doi.org/10.1002/biof.1924openalex-snapshot
Topical application of gemcitabine generates microvesicle particles in human and murine skin
inferred← citeshttps://doi.org/10.1002/cam4.1386openalex-snapshot
Strategy to targeting the immune resistance and novel therapy in colorectal cancer
inferred← citeshttps://doi.org/10.1002/cam4.2235openalex-snapshot
Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild‐type KRAS exon 2 metastatic colorectal cancer
inferred← citeshttps://doi.org/10.1002/cam4.3095openalex-snapshot
Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review
inferred← citeshttps://doi.org/10.1002/cam4.3371openalex-snapshot
A specific microRNA profile as predictive biomarker for systemic treatment in patients with metastatic colorectal cancer
inferred← citeshttps://doi.org/10.1002/cam4.3757openalex-snapshot
The impact of primary tumor sidedness on survival in early‐onset colorectal cancer by stage: A National Veterans Affairs retrospective analysis
inferred← citeshttps://doi.org/10.1002/cam4.3876openalex-snapshot
First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
inferred← citeshttps://doi.org/10.1002/cam4.3940openalex-snapshot
Surgical resection and survival outcomes in metastatic young adult colorectal cancer patients
inferred← citeshttps://doi.org/10.1002/cam4.4581openalex-snapshot
Risk factors for venous thromboembolism in metastatic colorectal cancer with contemporary treatment: A SEER‐Medicare analysis
inferred← citeshttps://doi.org/10.1002/cam4.5133openalex-snapshot
Time to treatment initiation and its impact on real‐world survival in metastatic colorectal cancer and pancreatic cancer
inferred← citeshttps://doi.org/10.1002/cam4.6048openalex-snapshot
Multi‐omic analysis in normal colon organoids highlights MSH4 as a novel marker of defective mismatch repair in Lynch syndrome and microsatellite instability
inferred← citeshttps://doi.org/10.1002/cam4.6196openalex-snapshot
Treatment outcome comparisons of first‐line targeted therapy in patients with KRAS wild‐type metastatic colorectal cancer: A nationwide database study
inferred← citeshttps://doi.org/10.1002/cam4.6223openalex-snapshot
Prognostic value of Lynch syndrome, BRAFV600E, and RAS mutational status in dMMR / MSI‐H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts
inferred← citeshttps://doi.org/10.1002/cncr.31552openalex-snapshot
Multicenter, randomized, double‐blind phase 2 trial of FOLFIRI with regorafenib or placebo as second‐line therapy for metastatic colorectal cancer
inferred← citeshttps://doi.org/10.1002/cncr.31795openalex-snapshot
Cost‐effectiveness of immune checkpoint inhibitors for microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer
inferred← citeshttps://doi.org/10.1002/cncr.32347openalex-snapshot
Recent trends in the age at diagnosis of colorectal cancer in the US National Cancer Data Base, 2004‐2015
inferred← citeshttps://doi.org/10.1002/cncr.33649openalex-snapshot
Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931)
inferred← citeshttps://doi.org/10.1002/cncr.35007openalex-snapshot
Physical activity in recurrent colon cancer: Cancer and Leukemia Group B/SWOG 80702 (Alliance)
inferred← citeshttps://doi.org/10.1002/cncr.35807openalex-snapshot
A phase 2 study of adjuvant chemotherapy with 5‐fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G)
inferred← citeshttps://doi.org/10.1002/cnr2.70668openalex-snapshot
AZD6738 (Ceralasertib) Enhances Trifluridine's Antitumor Effect in 5‐ FU –Resistant Colorectal Cancer Cells
inferred← citeshttps://doi.org/10.1002/ijc.32320openalex-snapshot
Non‐V600E BRAF mutations and EGFR signaling pathway in colorectal cancer
inferred← citeshttps://doi.org/10.1002/ijc.32879openalex-snapshot
Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study
inferred← citeshttps://doi.org/10.1002/ijc.33200openalex-snapshot
Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real‐life data
inferred← citeshttps://doi.org/10.1002/ijc.33810openalex-snapshot
Genome‐wide association studies of survival in 1520 cancer patients treated with bevacizumab‐containing regimens
inferred← citeshttps://doi.org/10.1002/ijc.34230openalex-snapshot
Dietary fat in relation to all‐cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/ SWOG 80405
inferred← citeshttps://doi.org/10.1002/jcp.29494openalex-snapshot
PD‐1/PD‐L1‐dependent immune response in colorectal cancer
inferred← citeshttps://doi.org/10.1002/jhbp.1252openalex-snapshot
Comprehensive data of 4502 patients newly diagnosed with colorectal liver metastasis between 2015 and 2017, and prognostic data of 2427 patients newly diagnosed with colorectal liver metastasis in 2013 and 2014: Third report of a nationwide survey in Japan
inferred← citeshttps://doi.org/10.1002/jso.25421openalex-snapshot
Systemic treatment for metastatic colorectal cancer in the era of precision medicine
inferred← citeshttps://doi.org/10.1002/jso.25424openalex-snapshot
Treatment sequencing for simultaneous colorectal liver metastases
inferred← citeshttps://doi.org/10.1002/jso.26911openalex-snapshot
Hepatic arterial infusion pump chemotherapy combined with systemic therapy for patients with advanced colorectal liver metastases: Outcomes in a newly established program
inferred← citeshttps://doi.org/10.1002/jso.27295openalex-snapshot
Colorectal cancer: Review of signaling pathways and associated therapeutic strategies
inferred← citeshttps://doi.org/10.1002/jso.27944openalex-snapshot
Liver Resection With Extrahepatic Disease: A Population‐Based Analysis of Thoughtful Selection
inferred← citeshttps://doi.org/10.1002/onco.13870openalex-snapshot
The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study
inferred← citeshttps://doi.org/10.1002/path.5347openalex-snapshot
BTK inhibitors synergise with 5‐FU to treat drug‐resistant TP53‐null colon cancers
inferred← citeshttps://doi.org/10.1002/pbc.27941openalex-snapshot
Colorectal cancer in adolescents and young adults: Defining a growing threat
inferred← citeshttps://doi.org/10.1002/sim.70339openalex-snapshot
Covariate‐Adjusted Group Sequential Comparisons of Survival Probabilities
inferred← citeshttps://doi.org/10.1007/978-3-030-02771-1_8openalex-snapshot
Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All
inferred← citeshttps://doi.org/10.1007/978-3-030-06225-5_21openalex-snapshot
Postoperative Oncologic Management of Colorectal Cancer Emergencies
inferred← citeshttps://doi.org/10.1007/978-3-030-25486-5_23openalex-snapshot
Sequencing of Systemic Chemotherapy for Unresectable CRLM
inferred← citeshttps://doi.org/10.1007/978-3-030-58846-5_21openalex-snapshot
Chemotherapy and Targeted Drugs for Patients with Metastatic Colorectal Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-62640-2_26openalex-snapshot
Importance of Systemic Chemotherapy in Advanced Peritoneal Metastasis
inferred← citeshttps://doi.org/10.1007/978-3-031-09323-4_24openalex-snapshot
Downsizing Chemotherapy for Liver Metastases from Colorectal Cancer
inferred← citeshttps://doi.org/10.1007/978-3-031-09323-4_32openalex-snapshot
Treatment Refractory Metastatic Colorectal Cancer
inferred← citeshttps://doi.org/10.1007/978-3-662-54500-3_26openalex-snapshot
Stellenwert der systemischen Chemotherapie bei fortgeschrittener peritonealer Metastasierung
inferred← citeshttps://doi.org/10.1007/s00053-018-0312-2openalex-snapshot
Oligometastasierung beim kolorektalen Karzinom – moderne Therapiekonzepte
inferred← citeshttps://doi.org/10.1007/s00053-022-00601-4openalex-snapshot
Therapiestrategien beim synchron metastasierten Kolonkarzinom
inferred← citeshttps://doi.org/10.1007/s00066-024-02291-xopenalex-snapshot
Multi-institutional analysis of extracranial oligometastatic colorectal cancer patients treated with stereotactic body radiation therapy: TROD 02-008 study
inferred← citeshttps://doi.org/10.1007/s00104-018-0661-yopenalex-snapshot
Oligometastasierung beim kolorektalen Karzinom – moderne Therapiekonzepte
inferred← citeshttps://doi.org/10.1007/s00104-021-01486-7openalex-snapshot
Einfluss der Molekularpathologie auf die onkologische Chirurgie des kolorektalen Karzinoms
inferred← citeshttps://doi.org/10.1007/s00108-019-00682-2openalex-snapshot
Therapie mit monoklonalen Antikörpern in der Gastroenterologie
inferred← citeshttps://doi.org/10.1007/s00108-026-02133-1openalex-snapshot
Personalisierte Arzneimitteltherapie des kolorektalen Karzinoms
inferred← citeshttps://doi.org/10.1007/s00198-025-07575-1openalex-snapshot
Comparative analysis of osteoporotic versus pathologic fracture in metastatic colorectal cancer patients
inferred← citeshttps://doi.org/10.1007/s00210-025-04921-2openalex-snapshot
Effects of bevacizumab combined with anti-epidermal growth factor receptor monoclonal antibody-targeted drugs in patients with metastatic colorectal cancer
inferred← citeshttps://doi.org/10.1007/s00270-019-02278-7openalex-snapshot
Chemotherapy, Still an Option in the Twenty-First Century in Metastatic Colorectal Cancer?
inferred← citeshttps://doi.org/10.1007/s00270-019-02284-9openalex-snapshot
Liver-Directed and Systemic Therapies for Colorectal Cancer Liver Metastases
inferred← citeshttps://doi.org/10.1007/s00280-017-3458-7openalex-snapshot
A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study
inferred← citeshttps://doi.org/10.1007/s00280-018-3713-6openalex-snapshot
Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
inferred← citeshttps://doi.org/10.1007/s00280-018-3738-xopenalex-snapshot
A phase II trial of the effect of perindopril on hand–foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC
inferred← citeshttps://doi.org/10.1007/s00280-019-03943-xopenalex-snapshot
Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer
inferred← citeshttps://doi.org/10.1007/s00280-019-04014-xopenalex-snapshot
A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects
inferred← citeshttps://doi.org/10.1007/s00330-018-5967-0openalex-snapshot
Tumor-size responses to first-line is a predictor of overall survival in metastatic colorectal cancer
inferred← citeshttps://doi.org/10.1007/s00384-020-03667-yopenalex-snapshot
The value of circulation tumor DNA in predicting postoperative recurrence of colorectal cancer: a meta-analysis
inferred← citeshttps://doi.org/10.1007/s00384-020-03748-yopenalex-snapshot
Serum IL-8 level as a candidate prognostic marker of response to anti-angiogenic therapy for metastatic colorectal cancer
inferred← citeshttps://doi.org/10.1007/s00384-021-04028-zopenalex-snapshot
Efficacy and safety of immune checkpoint inhibitors in colorectal cancer: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s00384-023-04442-5openalex-snapshot
Different doses of bevacizumab in combination with chemotherapy for advanced colorectal cancer: a meta-analysis and Bayesian analysis
inferred← citeshttps://doi.org/10.1007/s00384-024-04745-1openalex-snapshot
Impact on survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasis
inferred← citeshttps://doi.org/10.1007/s00432-019-02924-0openalex-snapshot
Patient-reported outcomes and health-related quality of life for cetuximab versus bevacizumab in metastatic colorectal cancer: a prospective cohort study
inferred← citeshttps://doi.org/10.1007/s00432-020-03167-0openalex-snapshot
Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study
inferred← citeshttps://doi.org/10.1007/s00432-020-03233-7openalex-snapshot
Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases
inferred← citeshttps://doi.org/10.1007/s00432-023-05141-yopenalex-snapshot
Impact of encorafenib on survival of patients with BRAFV600E-mutant metastatic colorectal cancer in a real-world setting
inferred← citeshttps://doi.org/10.1007/s00432-024-05805-3openalex-snapshot
Temporal dynamics of RAS mutations in circulating tumor DNA in metastatic colorectal cancer: clinical significance of mutation loss during treatment
inferred← citeshttps://doi.org/10.1007/s00464-018-6250-9openalex-snapshot
Cost-effectiveness analysis of laparoscopic versus open surgery in colon cancer
inferred← citeshttps://doi.org/10.1007/s00520-020-05972-2openalex-snapshot
Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study
inferred← citeshttps://doi.org/10.1007/s00520-024-08807-6openalex-snapshot
Oxaliplatin-induced peripheral neuropathy with hepatic arterial versus intravenous infusion in metastatic colorectal cancer
inferred← citeshttps://doi.org/10.1007/s00595-025-03125-8openalex-snapshot
Surgical strategy for repeated metastasectomy for advanced colorectal cancer with synchronous liver metastases
inferred← citeshttps://doi.org/10.1007/s00761-019-0611-4openalex-snapshot
MSI und Tumormutationslast beim kolorektalen Karzinom
inferred← citeshttps://doi.org/10.1007/s00761-020-00777-8openalex-snapshot
Therapeutische Relevanz molekularer Marker beim kolorektalen Karzinom
inferred← citeshttps://doi.org/10.1007/s00761-020-00875-7openalex-snapshot
Systemische Therapie des metastasierten Kolonkarzinoms
inferred← citeshttps://doi.org/10.1007/s00761-023-01302-3openalex-snapshot
Therapie von Lebermetastasen
inferred← citeshttps://doi.org/10.1007/s10147-020-01619-8openalex-snapshot
Magnitude of advantage in tumor response contributes to a better correlation between treatment effects on overall survival and progression-free survival: a literature-based meta-analysis of clinical trials in patients with metastatic colorectal cancer
inferred← citeshttps://doi.org/10.1007/s10147-020-01730-wopenalex-snapshot
Clinicopathological characteristics and prognosis analysis of ovarian metastases in colorectal cancer: a single-center experience
inferred← citeshttps://doi.org/10.1007/s10147-022-02208-7openalex-snapshot
Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum
inferred← citeshttps://doi.org/10.1007/s10147-025-02831-0openalex-snapshot
Effect of pretreatment vascular endothelial growth factor inhibitor use on the safety and efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer
inferred← citeshttps://doi.org/10.1007/s10555-020-09913-7openalex-snapshot
Current therapy of advanced colorectal cancer according to RAS/RAF mutational status
inferred← citeshttps://doi.org/10.1007/s10555-023-10158-3openalex-snapshot
Colorectal cancer: a comprehensive review of carcinogenesis, diagnosis, and novel strategies for classified treatments
inferred← citeshttps://doi.org/10.1007/s10637-021-01205-3openalex-snapshot
Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer
inferred← citeshttps://doi.org/10.1007/s10637-024-01443-1openalex-snapshot
Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer
inferred← citeshttps://doi.org/10.1007/s11096-022-01415-6openalex-snapshot
The effectiveness and safety of bevacizumab versus cetuximab in the treatment of colorectal cancer: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s11523-019-00647-3openalex-snapshot
MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer
inferred← citeshttps://doi.org/10.1007/s11547-023-01710-wopenalex-snapshot
Radiomics and machine learning analysis by computed tomography and magnetic resonance imaging in colorectal liver metastases prognostic assessment
inferred← citeshttps://doi.org/10.1007/s11596-020-2298-6openalex-snapshot
Feasibility of MRI Radiomics for Predicting KRAS Mutation in Rectal Cancer
inferred← citeshttps://doi.org/10.1007/s11605-019-04154-8openalex-snapshot
Repeat Hepatectomy After Major Hepatectomy for Colorectal Liver Metastases
inferred← citeshttps://doi.org/10.1007/s11655-024-4115-8openalex-snapshot
Chinese Medicine in Colorectal Cancer Treatment: From Potential Targets and Mechanisms to Clinical Application
inferred← citeshttps://doi.org/10.1007/s11725-016-0670-2openalex-snapshot
Compte-rendu du congrès de l’ASCO 2016
inferred← citeshttps://doi.org/10.1007/s11725-017-0734-yopenalex-snapshot
Compte-rendu du congrès de l’ASCO 2017
inferred← citeshttps://doi.org/10.1007/s11864-023-01142-8openalex-snapshot
Selecting Optimal First-Line Treatment for Microsatellite Stable and Non-Mutated RAS/BRAF Metastatic Colorectal Cancer
inferred← citeshttps://doi.org/10.1007/s11888-018-0410-0openalex-snapshot
Evolving Tissue and Circulating Biomarkers as Prognostic and Predictive Tools in Colorectal Cancer
inferred← citeshttps://doi.org/10.1007/s11888-018-0414-9openalex-snapshot
What Is the Best Systemic Therapy for Left-sided RAS Wild-type Metastatic Colorectal Cancer?
inferred← citeshttps://doi.org/10.1007/s11888-019-00430-6openalex-snapshot
Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review
inferred← citeshttps://doi.org/10.1007/s11888-021-00464-9openalex-snapshot
Current Status of Biologics in Perioperative Treatment for Resectable or Borderline Resectable Liver Metastases
inferred← citeshttps://doi.org/10.1007/s11888-021-00466-7openalex-snapshot
Precision Medicine for the Treatment of Colorectal Cancer: the Evolution and Status of Molecular Profiling and Biomarkers
inferred← citeshttps://doi.org/10.1007/s11888-022-00475-0openalex-snapshot
Current Updates on HER2–Directed Therapies in Metastatic Colorectal Cancer
inferred← citeshttps://doi.org/10.1007/s11912-021-01137-4openalex-snapshot
Circulating Tumour DNA and Colorectal Cancer: the Next Revolutionary Biomarker?
inferred← citeshttps://doi.org/10.1007/s11912-022-01256-6openalex-snapshot
Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge
inferred← citeshttps://doi.org/10.1007/s11912-024-01548-zopenalex-snapshot
Advancements in the Management of Synchronous Colorectal Liver Metastases: A Comprehensive Review of Surgical, Systemic, and Local Treatment Modalities
inferred← citeshttps://doi.org/10.1007/s12029-020-00372-5openalex-snapshot
Effect of Time to Surgery of Colorectal Liver Metastases on Survival
inferred← citeshttps://doi.org/10.1007/s12029-022-00900-5openalex-snapshot
Oligometastatic Colorectal Cancer: A Review of Definitions and Patient Selection for Local Therapies
inferred← citeshttps://doi.org/10.1007/s12029-026-01564-1openalex-snapshot
HER2-Targeted Therapy for Metastatic Colorectal Cancer: Current Evidence, Patient Selection, and Practical Treatment Sequencing
inferred← citeshttps://doi.org/10.1007/s12029-026-01595-8openalex-snapshot
Comparative Effectiveness and Safety of FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Metastatic Colorectal Cancer: A GRADE-assessed Systematic Review and Meta-analysis
inferred← citeshttps://doi.org/10.1007/s12032-025-02670-zopenalex-snapshot
Nanomedicine innovations in colon and rectal cancer: advances in targeted drug and gene delivery systems
inferred← citeshttps://doi.org/10.1007/s12094-019-02215-7openalex-snapshot
Dynamic monitoring of HER2 amplification in circulating DNA of patients with metastatic colorectal cancer treated with cetuximab
inferred← citeshttps://doi.org/10.1007/s12094-020-02402-xopenalex-snapshot
Prognostic value of molecular biomarkers in patients with metastatic colorectal cancer: a real-world study
inferred← citeshttps://doi.org/10.1007/s12094-023-03369-1openalex-snapshot
Delphi consensus for the third-line treatment of metastatic colorectal cancer
inferred← citeshttps://doi.org/10.1007/s12094-024-03513-5openalex-snapshot
Constructing a prognostic model for colorectal cancer with synchronous liver metastases after preoperative chemotherapy: a study based on SEER and an external validation cohort
inferred← citeshttps://doi.org/10.1007/s12253-017-0365-5openalex-snapshot
Role of Anti-Epidermal Growth Factor Receptor Therapy Compared with Anti-Vascular Endothelial Growth Factor Therapy for Metastatic Colorectal Cancer: an Update Meta-Analysis of Randomized Clinical Trials
inferred← citeshttps://doi.org/10.1007/s12312-019-0653-yopenalex-snapshot
FIRE-5-Studie (AIO TF-0118)
inferred← citeshttps://doi.org/10.1007/s12325-018-0791-0openalex-snapshot
An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review
inferred← citeshttps://doi.org/10.1007/s12325-020-01447-2openalex-snapshot
Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review
inferred← citeshttps://doi.org/10.1007/s13577-026-01435-8openalex-snapshot
Integrative bulk and single-cell transcriptomics identify a recurrence-prognostic risk model with exploratory associations with treatment-response phenotypes in colorectal cancer
inferred← citeshttps://doi.org/10.1007/s15004-020-8020-9openalex-snapshot
Therapiesequenz beim metastasierten kolorektalen Karzinom
inferred← citeshttps://doi.org/10.1007/s40258-019-00482-7openalex-snapshot
Budget Impact Analysis of Molecular Lymph Node Staging Versus Conventional Histopathology Staging in Colorectal Carcinoma
inferred← citeshttps://doi.org/10.1007/s40258-020-00626-0openalex-snapshot
The Budget Impact of Monoclonal Antibodies Used to Treat Metastatic Colorectal Cancer in Minas Gerais, Brazil
inferred← citeshttps://doi.org/10.1007/s43440-024-00652-yopenalex-snapshot
A comprehensive update on the potential of curcumin to enhance chemosensitivity in colorectal cancer
inferred← citeshttps://doi.org/10.1007/s44178-023-00023-2openalex-snapshot
CACA guidelines for holistic integrative management of rectal cancer
inferred← citeshttps://doi.org/10.1016/b978-0-323-90055-3.00016-8openalex-snapshot
A roadmap for medical treatment of metastatic CRC
inferred← citeshttps://doi.org/10.1016/b978-0-323-90190-1.00007-xopenalex-snapshot
Antiangiogenic agents in the treatment of colorectal, gastric, and gastroesophageal junction adenocarcinoma
inferred← citeshttps://doi.org/10.1016/bs.adgen.2024.08.004openalex-snapshot
Personalised medicine based on host genetics and microbiota applied to colorectal cancer
inferred← citeshttps://doi.org/10.1016/j.annonc.2019.12.007openalex-snapshot
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database
inferred← citeshttps://doi.org/10.1016/j.annonc.2021.03.206openalex-snapshot
Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines
inferred← citeshttps://doi.org/10.1016/j.annonc.2024.11.012openalex-snapshot
Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study
inferred← citeshttps://doi.org/10.1016/j.annonc.2025.08.001openalex-snapshot
Risk of disease progression in first-line metastatic colorectal cancer therapy to guide disease reassessments―analysis of 11 trials by AIO and GONO
inferred← citeshttps://doi.org/10.1016/j.annonc.2025.10.008openalex-snapshot
Positioning EGFR re-treatment in modern metastatic colorectal cancer: insights from PARERE
inferred← citeshttps://doi.org/10.1016/j.annonc.2026.03.005openalex-snapshot
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
inferred← citeshttps://doi.org/10.1016/j.bbcan.2025.189281openalex-snapshot
The tumor microenvironment and dendritic cells: Developers of pioneering strategies in colorectal cancer immunotherapy?
inferred← citeshttps://doi.org/10.1016/j.biopha.2020.109947openalex-snapshot
Early prediction of tumor response after radiotherapy in combination with cetuximab in nasopharyngeal carcinoma using 99m Tc-duramycin imaging
inferred← citeshttps://doi.org/10.1016/j.biopha.2020.110377openalex-snapshot
Chemo-immunotherapy with doxorubicin prodrug and erythrocyte membrane-enveloped polymer nano-vaccine enhances antitumor activity
inferred← citeshttps://doi.org/10.1016/j.bulcan.2018.01.009openalex-snapshot
Médecine de précision : une avancée majeure dans des situations spécifiques, un mythe dans les cancers réfractaires ?
inferred← citeshttps://doi.org/10.1016/j.bulcan.2020.04.017openalex-snapshot
Cancers colorectaux avec mutation V600E de BRAF : où en sommes-nous ?
inferred← citeshttps://doi.org/10.1016/j.canlet.2025.217643openalex-snapshot
FUT2-dependent fucosylation of LAMP1 promotes the apoptosis of colorectal cancer cells by regulating the autophagy-lysosomal pathway
inferred← citeshttps://doi.org/10.1016/j.ccell.2018.11.003openalex-snapshot
The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients
inferred← citeshttps://doi.org/10.1016/j.cct.2020.106037openalex-snapshot
Design, data linkage, and implementation considerations in the first cooperative group led study assessing financial outcomes in cancer patients and their informal caregivers
inferred← citeshttps://doi.org/10.1016/j.cct.2023.107273openalex-snapshot
Use of acupuncture with acupressure in addition to standard-of-care cryotherapy to decrease chemotherapy-associated neuropathy in patients with gastrointestinal malignancies receiving oxaliplatin-based chemotherapy: Study protocol for a randomized, controlled pilot and feasibility study
inferred← citeshttps://doi.org/10.1016/j.clcc.2017.11.001openalex-snapshot
Primary Tumor Location and Survival in the General Population With Metastatic Colorectal Cancer
inferred← citeshttps://doi.org/10.1016/j.clcc.2018.02.011openalex-snapshot
A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer
inferred← citeshttps://doi.org/10.1016/j.clcc.2018.05.009openalex-snapshot
Previous Bevacizumab and Efficacy of Later Anti–Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry
inferred← citeshttps://doi.org/10.1016/j.clcc.2018.07.007openalex-snapshot
Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial
inferred← citeshttps://doi.org/10.1016/j.clcc.2019.02.008openalex-snapshot
A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology
inferred← citeshttps://doi.org/10.1016/j.clcc.2019.06.001openalex-snapshot
Lung Metastasis Predicts Better Prognosis in Metastatic Colorectal Cancer With Mutated KRAS
inferred← citeshttps://doi.org/10.1016/j.clcc.2019.07.003openalex-snapshot
ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK
inferred← citeshttps://doi.org/10.1016/j.clcc.2019.09.002openalex-snapshot
Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System
inferred← citeshttps://doi.org/10.1016/j.clcc.2020.02.008openalex-snapshot
Systemic Chemotherapy for Metastatic Colitis-Associated Cancer Has a Worse Outcome Than Sporadic Colorectal Cancer: Matched Case Cohort Analysis
inferred← citeshttps://doi.org/10.1016/j.clcc.2020.02.014openalex-snapshot
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected
inferred← citeshttps://doi.org/10.1016/j.clcc.2020.03.003openalex-snapshot
Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial
inferred← citeshttps://doi.org/10.1016/j.clcc.2020.04.003openalex-snapshot
Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion
inferred← citeshttps://doi.org/10.1016/j.clcc.2020.05.009openalex-snapshot
Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial
inferred← citeshttps://doi.org/10.1016/j.clcc.2021.12.002openalex-snapshot
Assessment of Metastatic Colorectal Cancer Patients’ Preferences for Biologic Treatments in Germany Using a Discrete Choice Experiment
inferred← citeshttps://doi.org/10.1016/j.clcc.2022.08.002openalex-snapshot
WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAFV600E Mutant Metastatic Colorectal Cancer: A Multi-Institutional Registry-Based Study (BRACELET Study)
inferred← citeshttps://doi.org/10.1016/j.clcc.2023.08.006openalex-snapshot
Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer
inferred← citeshttps://doi.org/10.1016/j.clcc.2023.12.001openalex-snapshot
Prognostic Impact of Primary Tumor Sidedness in Stage III Colorectal Cancer: Real-World Evidence from a Brazilian Cohort
inferred← citeshttps://doi.org/10.1016/j.clcc.2025.04.001openalex-snapshot
Exploring Real-World Outcomes of First Line EGFR Inhibitor Use, Cetuximab Versus Panitumumab, in Patients with Left-Sided, RAS Wild-Type, Metastatic Colorectal Cancer
inferred← citeshttps://doi.org/10.1016/j.clcc.2026.05.003openalex-snapshot
Dual CTLA-4/PD-1 Blockade Versus Anti–PD-1 in MSI-H Metastatic Colorectal Cancer: Early Survival Benefit and Exploratory Clinical Predictors
inferred← citeshttps://doi.org/10.1016/j.clinre.2022.101888openalex-snapshot
MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer
inferred← citeshttps://doi.org/10.1016/j.clnu.2020.01.009openalex-snapshot
The effect of nutritional counseling on muscle mass and treatment outcome in patients with metastatic colorectal cancer undergoing chemotherapy: A randomized controlled trial
inferred← citeshttps://doi.org/10.1016/j.clon.2022.02.011openalex-snapshot
A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer
inferred← citeshttps://doi.org/10.1016/j.clon.2022.04.012openalex-snapshot
Real-World Assessment of Cancer Drugs Using Local Data Uploaded to the Systemic Anti-Cancer Therapy Dataset in England
inferred← citeshttps://doi.org/10.1016/j.clon.2023.12.003openalex-snapshot
First-line Palliative Chemotherapy for Colorectal Cancer: a Population-based Analysis of Delivery and Outcomes in a Single-payer Health System
inferred← citeshttps://doi.org/10.1016/j.clon.2024.01.010openalex-snapshot
Big Data and Colorectal Cancer: the Revolution will be Personalised
inferred← citeshttps://doi.org/10.1016/j.cmet.2025.06.002openalex-snapshot
Microbial riboflavin inhibits ceramide synthase 3 to lower ceramide (d18:1/26:0) and delay colorectal cancer progression
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2019.05.004openalex-snapshot
The treatment of rectal cancer with synchronous liver metastases: A matter of strategy
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2019.102823openalex-snapshot
Tumor sidedness and efficacy of first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer: A network meta-analysis
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2020.102877openalex-snapshot
Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2022.103646openalex-snapshot
Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAF-mutant metastatic and/or unresectable colorectal cancer
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2023.104057openalex-snapshot
The mechanism investigation of mutation genes in liver and lung metastasis of colorectal cancer by using NGS technique
showing the first 200 of 892 · page through all 892
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.